Hasselbalch Hans Carl, Poulsen Anne, Skov Vibe, Kjær Lasse, Nielsen Claus Henrik, Poulsen Troesl Dirch
Ugeskr Laeger. 2020 Jun 15;182(25).
Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.
患有新冠肺炎的重症患者可能需要机械通气。急性呼吸衰竭的原因是肺部出现大量炎症反应，世界卫生组织不建议使用糖皮质激素进行治疗。一种罕见的血液疾病——病毒相关噬血细胞性淋巴组织细胞增生症综合征（HLS），其死亡率很高，且伴有类似的炎症反应综合征。Janus激酶（JAK）1/2抑制剂治疗对HLS非常有效。在这篇综述中，我们讨论了在新冠肺炎肺炎重症患者中使用JAK1/2抑制剂的理论依据和前景。
